Clinical trials performed within the Group

Scientific Program

The Group’s scientific program includes all phases of clinical research (phases 1 to 4). It also covers all types and subtypes of breast cancer: Hormone-receptor-positive – estrogen or progesterone (HR +); HER2 protein overexpression (HER2 +); Triple-negative, which does not involve hormone receptors nor those of the HER2 protein (HR- / HER2-); Genetic mutation (somatic / spontaneous or hereditary / transmitted), as well as all stages of the disease or extent of cancer, from in situ and early stages to metastatic cancer.

Cancer SubtypeTime of treatmentTreatment Types
HR+/HER2-NeoadjuvantChemotherapy
HR-/HER2+AdjuvantHormonal therapy
HR-/HER2- (mutated or not)Post-NeoadjuvantImmunotherapy
HR+/HER2+Prevention
Genetic Mutations Radiation therapy
Supportive therapy
Surgery
Targeted therapy

Clinical Trials Performed Within the Group

The consortium is presently involved in 15 or so clinical trials and is considering new ones regularly. Please refer to the table below to see what trials are ongoing at the Group’s hospitals.

Cancer SubtypeStudy NameSponsorParticipating HospitalsStatus
HR+ & HER2-TROPICS-02 (IMMU132-09)
Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens (TROPICS-02)
Immunomedics Inc.CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'ESTRIE – CHUS
In preparation
HR+ & HER2-NSABP-B58 / MonarchE
Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Eli Lilly in collaboration with NSABP Foundation Inc.CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'ESTRIE – CHUS

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CHU DE QUEBEC – UNIVERSITE LAVAL
Closed to recruitment
HR+ & HER2-NeaOnQ
A prospective clinical utility and economic impact study of the Oncotype DX® Recurrence Score in in node-positive patients and in candidates for neoadjuvant therapy in Quebec
CHUM in collaboration with Genomic HealthCENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CHU DE QUEBEC – UNIVERSITE LAVAL

MCGILL UNIVERSITY HEALTH CENTER (MUHC)
In recruitment
HR+ & HER2-CONTESSA (ODO-TE-B301)
Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Odonate Therapeutics, Inc.CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DE L'ESTRIE – CHUS

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / JEWISH GENERAL HOSPITAL

CHU DE QUEBEC – UNIVERSITE LAVAL

MCGILL UNIVERSITY HEALTH CENTER (MUHC)
Closed to recruitment
ER+ & HER2-EMERALD (RAD1901-308)
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial (EMERALD)
Radius Pharmaceuticals, Inc. CHU DE QUEBEC – UNIVERSITE LAVAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

MCGILL UNIVERSITY HEALTH CENTER (MUHC)
In preparation
ER+ & HER2-CheckMate 7A8 (CA209-7A8)
Randomized, Non-comparative Neoadjuvant Phase II Study in Patients With ER+/HER2- Breast Cancer >= 2 cm With Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole (CheckMate 7A8)
Bristol-Myers SquibbCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DE L'ESTRIE – CHUS
In preparation
ER+ & HER2-CheckMate 7FL (CA209-7FL)
Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL)
Bristol-Myers SquibbCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'ESTRIE – CHUS

CIUSSS DE L’OUEST-DE-L’ÎLE-DE-MONTRÉAL/ ST. MARY'S HOSPITAL
In preparation
ER+ & HER2-KEYNOTE-756
Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Breast Cancer
Merck Sharp & Dohme Corp.CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / JEWISH GENERAL HOSPITAL

CHU DE QUEBEC – UNIVERSITE LAVAL

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT
In recruitment
ER+ & HER2-NSABP-FB13
Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer
NSABP Foundation Inc. CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

MCGILL UNIVERSITY HEALTH CENTER (MUHC)

CHU DE QUEBEC – UNIVERSITE LAVAL

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT
In recruitment
HR+ & HER2-NATALEE (TRIO033)
Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer
Novartis Pharmaceuticals in collaboration with Translational Research in OncologyCENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

MCGILL UNIVERSITY HEALTH CENTER (MUHC)

CHU DE QUEBEC – UNIVERSITE LAVAL

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DE L'ESTRIE – CHUS
In recruitment
HR+ & HER2-XENERA
Multi-center, double-blind, placebo-controlled, randomised phase II trial to compare the efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women in post-menopausal women with Hormone Receptor Positive (HR+) and HER2- negative metastatic breast cancer and non-visceral disease
Boehringer IngelheimMCGILL UNIVERSITY HEALTH CENTER (MUHC)

CHU DE QUEBEC – UNIVERSITE LAVAL
In recruitment
HER2- & BRCA1/2LUCY
Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study - A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations
Astra Zeneca in collaboration with ParexelCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CHU DE QUEBEC – UNIVERSITE LAVAL
Closed to recruitment
HR- & HER2- (Triple negative)NSABP-B59
Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
NSABP Foundation Inc in collaboration with Genentech Inc. CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

MCGILL UNIVERSITY HEALTH CENTER (CUSM)

CHU DE QUEBEC – UNIVERSITE LAVAL

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT
In recruitment
HR- & HER2- (Triple negative)ATTAIN
Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Nektar TherapeuticsMCGILL UNIVERSITY HEALTH CENTER (MUHC)Closed to recruitment
HR+ & HER2- / ER- & HER2- / HER2+TRIO-030
Pre-surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist ODM-20
Translational Research in Oncology (TRIO)CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CHU DE QUEBEC – UNIVERSITE LAVAL

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

MCGILL UNIVERSITY HEALTH CENTER (MUHC)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT
Closed to recruitment
HR+ & HER2- CONTESSA 2
Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane
Odonate Therapeutics Inc.ENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CHU DE QUEBEC – UNIVERSITE LAVAL

MCGILL UNIVERSITY HEALTH CENTER (MUHC)

CIUSSS DE L'ESTRIE – CHUS
In recruitment
HR- & HER2- (Triple negative) / HER2-CONTESSA-TRIO
Multicenter, Phase 2 Study of Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Elderly Patients With HER2 Negative MBC
Odonate Therapeutics Inc.CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

MCGILL UNIVERSITY HEALTH CENTER (MUHC)

CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
In recruitment
Cancer SubtypeStudy NameSponsorParticipating HospitalsStatus
HR+ & HER2-TROPICS-02 (IMMU132-09)
Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens (TROPICS-02)
Immunomedics Inc.CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'ESTRIE – CHUS
In preparation
HR+ & HER2-NSABP-B58 / MonarchE
Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Eli Lilly in collaboration with NSABP Foundation Inc.CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'ESTRIE – CHUS

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CHU DE QUEBEC – UNIVERSITE LAVAL
Closed to recruitment
HR+ & HER2-NeaOnQ
A prospective clinical utility and economic impact study of the Oncotype DX® Recurrence Score in in node-positive patients and in candidates for neoadjuvant therapy in Quebec
CHUM in collaboration with Genomic HealthCENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CHU DE QUEBEC – UNIVERSITE LAVAL

MCGILL UNIVERSITY HEALTH CENTER (MUHC)
In recruitment
HR+ & HER2-CONTESSA (ODO-TE-B301)
Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Odonate Therapeutics, Inc.CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DE L'ESTRIE – CHUS

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / JEWISH GENERAL HOSPITAL

CHU DE QUEBEC – UNIVERSITE LAVAL

MCGILL UNIVERSITY HEALTH CENTER (MUHC)
Closed to recruitment
ER+ & HER2-EMERALD (RAD1901-308)
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial (EMERALD)
Radius Pharmaceuticals, Inc. CHU DE QUEBEC – UNIVERSITE LAVAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

MCGILL UNIVERSITY HEALTH CENTER (MUHC)
In preparation
ER+ & HER2-CheckMate 7A8 (CA209-7A8)
Randomized, Non-comparative Neoadjuvant Phase II Study in Patients With ER+/HER2- Breast Cancer >= 2 cm With Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole (CheckMate 7A8)
Bristol-Myers SquibbCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DE L'ESTRIE – CHUS
In preparation
ER+ & HER2-CheckMate 7FL (CA209-7FL)
Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL)
Bristol-Myers SquibbCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'ESTRIE – CHUS

CIUSSS DE L’OUEST-DE-L’ÎLE-DE-MONTRÉAL/ ST. MARY'S HOSPITAL
In preparation
ER+ & HER2-KEYNOTE-756
Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Breast Cancer
Merck Sharp & Dohme Corp.CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / JEWISH GENERAL HOSPITAL

CHU DE QUEBEC – UNIVERSITE LAVAL

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT
In recruitment
ER+ & HER2-NSABP-FB13
Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer
NSABP Foundation Inc. CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

MCGILL UNIVERSITY HEALTH CENTER (MUHC)

CHU DE QUEBEC – UNIVERSITE LAVAL

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT
In recruitment
HR+ & HER2-NATALEE (TRIO033)
Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer
Novartis Pharmaceuticals in collaboration with Translational Research in OncologyCENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

MCGILL UNIVERSITY HEALTH CENTER (MUHC)

CHU DE QUEBEC – UNIVERSITE LAVAL

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DE L'ESTRIE – CHUS
In recruitment
HR+ & HER2-XENERA
Multi-center, double-blind, placebo-controlled, randomised phase II trial to compare the efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women in post-menopausal women with Hormone Receptor Positive (HR+) and HER2- negative metastatic breast cancer and non-visceral disease
Boehringer IngelheimMCGILL UNIVERSITY HEALTH CENTER (MUHC)

CHU DE QUEBEC – UNIVERSITE LAVAL
In recruitment
HER2- & BRCA1/2LUCY
Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study - A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations
Astra Zeneca in collaboration with ParexelCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CHU DE QUEBEC – UNIVERSITE LAVAL
Closed to recruitment
HR- & HER2- (Triple negative)NSABP-B59
Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
NSABP Foundation Inc in collaboration with Genentech Inc. CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

MCGILL UNIVERSITY HEALTH CENTER (CUSM)

CHU DE QUEBEC – UNIVERSITE LAVAL

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT
In recruitment
HR- & HER2- (Triple negative)ATTAIN
Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Nektar TherapeuticsMCGILL UNIVERSITY HEALTH CENTER (MUHC)Closed to recruitment
HR+ & HER2- / ER- & HER2- / HER2+TRIO-030
Pre-surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist ODM-20
Translational Research in Oncology (TRIO)CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CHU DE QUEBEC – UNIVERSITE LAVAL

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

MCGILL UNIVERSITY HEALTH CENTER (MUHC)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT
Closed to recruitment
HR+ & HER2- CONTESSA 2
Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane
Odonate Therapeutics Inc.ENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CHU DE QUEBEC – UNIVERSITE LAVAL

MCGILL UNIVERSITY HEALTH CENTER (MUHC)

CIUSSS DE L'ESTRIE – CHUS
In recruitment
HR- & HER2- (Triple negative) / HER2-CONTESSA-TRIO
Multicenter, Phase 2 Study of Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Elderly Patients With HER2 Negative MBC
Odonate Therapeutics Inc.CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

MCGILL UNIVERSITY HEALTH CENTER (MUHC)

CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
In recruitment